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Abstract 
Fatty acid synthase (FAS) is an enzyme crucial for endogeneous lipogenesis in 
mammals. It synthesizes fatty acids for body uses by catalyzing the formation of 16-carbon 
palmitate from condensation of malonyl-coenzyme A and acetyl-coenzyme A. FAS 
over-expression and hyperactivity have been characterized in various human malignancies 
but with a low expression level in normal tissues，suggesting that FAS is a novel target for 
cancer therapy. In this study, growth-inhibitory effects of the FAS pharmacological 
inhibitors cerulenin and C75 were first investigated on a number of human cancer cell lines 
of different histotypes, including liver HepG2, lung A-549, colon CaCo-2, Colo201, 
SW480 and SW620, cervix HeLa, prostate LNCaP and PC-3, breast MCF-7 and SK-BR-3, 
and skin A-375. Results from the MTT study revealed that the cancer cell proliferation and 
viability was reduced dose- and time-dependently by 20.8% to 89.4% of the control levels 
after 24 and 48 h of treatment with 10 to 160 | iM of the inhibitor. Among the cancer cell 
lines tested, A-375 was found to be the most responsive one so that it was selected as the 
model to study the mechanism for growth inhibition. 
At the doses which A-375 growth was prominently retarded, neither cerulenin nor C75 
exerted cytotoxicity on the normal skin fibroblast HS68，suggesting that the inhibitors 
exerted preferential effect on the melanoma cells. DNA flow cytometric studies 
demonstrated that the FAS inhibitors accumulated G2/M cells preceding the elevation of 
i 
sub Gi or apoptotic cells with fragmented DNA. The proapoptotic effect of the FAS 
inhibitors was further confirmed using confocal microscopy with annexin-V FITC and 
‘propidium iodide staining. Results from the immunoblotting study further showed that 
poly(ADP-ribose) polymerase (PAR?) was cleaved, which is a hallmark feature of 
apoptosis, and procaspase-3 was processed into the active and smaller 17 and 19 kDa 
subimits, with concomitant depletion of caspase-3 inhibitors XIAP and survivin. Besides 
caspase-3, executioner procaspase-6 and -7 were also found to be processed into their 
active subimits and cleavage of lamin A/C，a substrate for proteolysis by the active caspase, 
was observed. On the other hand, administration of the 100 |j.M pan-caspase inhibitor 
Z-VAD-FMK completely rescued the cells from PARP cleavage, indicating that caspase 
activations play significant functions in the cerulenin- and C75-induced apoptosis. The FAS 
inhibitors were found to trigger both the extrinsic death receptor and intrinsic 
mitochondrial apoptotic pathways. Death receptor DR5 was elevated，and procaspase-8 and 
10 of the extrinsic pathway and procaspase-9 of the intrinsic pathway were processed into 
their active subimits. Flow cytometric TMRE studies revealed that both the inhibitors 
significantly altered the mitochondrial membrane potential together with the release of 
cytochrome c from mitochondria into the cytosol. Bid was depleted, possibly via 
proteolytic cleavage by caspase-8, indicating a possible linkage between both the pathways. 
To further support this hypothesis, administration of casapse-8 inhibitor Z-IETD-FMK 
ii 
rescued nearly all the cells from apoptosis, while caspase-9 inhibitor Z-LEHD-FMK only 
rescued a small proportion of cells. This suggests that the death receptor pathway probably 
takes a leader role in the cerulenin- and C75-induced apoptosis. Besides the 
pharmacological inhibitors, blockade of FAS expression by its molecular inhibitor small 
interfering RNA also generated the similar effects, suggesting that it was the depletion of 
FAS activity that initiated the molecular changes in the apoptosis. 
Results from this study suggest that FAS pharmacological and molecular inhibitors 
retard growth of melanoma A-375 cells, involving at least activation of caspase-dependent 
apoptosis. Further elucidations on the molecular mechanisms in apoptosis and cell cycle 
imposed by FAS inhibition would facilitate research on the synergism between FAS 
inhibition and some currently used drugs for more effective cancer treatments with less 











長抑制效果，包括肝癌H e p G 2、肺癌A - 5 4 9、結腸直腸癌C a C o - 2 � 
Colo201�SW480 及 S W 6 2 0 �子宮頸癌 H e L a �前列腺癌 LNCaP 及 P C - 3 � 
孔癌M C F - 7及S K - B R - 3及黑色素腫瘤A - 3 7 5 ’發現抑制劑對黑色素腫 
瘤細胞A - 3 7 5的抑制效果最強。在四甲基偶氮唾藍 ( M T T )法的細胞生長 
測試中， 1 0至 8 0 ^ i M脂肪酸合成酵抑制劑在 2 4及 4 8小時内有效抑制 
A-375共20 .8� /。至89 .4%之生長，其抑制效果更與時間及劑量相關。然 
而，2 0至8 0 j i M脂肪酸合成酶抑制劑不對纖維組織母細胞H S 6 8構成毒 
性，证明抑制劑主力抑制癌細胞生長而已。 
透過西方墨點法分析，淺藍菌素及 c 7 5在 2 4小時内均能導致黑色素 
腫瘤細胞的多聚ADP核糖多聚梅（PARP)分離；利用共輛焦顯微鏡技術 
iv 
之雄脂結合蛋白V異琉氣酸焚光素 ( A n n e x i n - V FITC)及破化丙唤(PI)標 
記，顯示脂肪酸合成醇抑制劑能令細胞调亡；流式細胞技術更註明脂肪 
酸合成酵抑制劑能誘導細胞發生G2/M期阻滞和細胞调亡；詳細的免疫轉 
漬分析指出脂肪酸合成晦抑制劑誘導琉耽數酸蛋白騰 - 3活化及分離成更 
細的17及19kDa的活化腺，從而減低调亡蛋白IAP中的XIAP及surviv in 
程度，抑制劑更誘導琉胱氧酸蛋白梅 - 6 � 7及核纖層蛋白A / C的分離；然 
而，梳胱數酸蛋白騰抑制劑Z-VAD-FMK能消除脂肪酸合成峰抑制劑所 






釋放到胞質溶膠中，同時誘導调亡蛋白B i d分離，証明外在的細胞膜死 
亡受體與内在的線粒體调亡途徑相連；在硫胱氧暖蛋白臃抑制劑實驗 
中，發現硫胱 I I酸蛋白晦 -8抑制劑Z-IETD-FMK較琉胱數酸蛋白晦-9抑 





梅及P A R P分離。 
本研究先指出脂肪酸合成晦 (FAS)抑制劑淺藍菌素及c75能有效誘導 
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‘ Chapter 3 
CHAPTER 1 General Introduction 
1.1 Fatty Acid Synthase (FAS) - 7-domain multifunctional enzyme 
Fatty Acid Synthase (FAS) is an enzyme crucial for endogenous lipogenesis in 
mammals. There are two types of FAS. Type I refers to a large，multifunctional enzyme 
with seven catalytic domains responsible for de novo lipogenesis in eukaryotic animal 
cells. On the other hand, Type I I is a monofunctional enzyme which exists only in plants 
and prokaryotes. 
1.1.1 Functions 
FAS functions to synthesize fatty acids for body uses by catalyzing the synthesis 
of 16-carbon palmitate from the condensation of malonyl-CoA and acetyl-CoA. FAS 
plays a crucial role in energy homeostasis by converting excess dietary carbon intake into 
fatty acids for storage. When there is high metabolic need, these fatty acids provide 
energy for biochemical reactions via p-oxidation catalyzed by carnitine 
0-palmitoyltransferase-1 (CPT-1). 
Since daily diet provides most fatty acids we need, endogenous synthesis is 
minimal. Therefore, FAS is expressed at low to even undetectable levels in most normal 
human tissues. Nevertheless, FAS is over-expressed in a large number of different human 
1 
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cancer histotypes to support their rapid growth and proliferation, despite high levels of 
endogenous ambient fatty acids. (Baron et al, 2004) 
1.1.2 Structure 
Each mammalian FAS monomer has 7 catalytic domains linked as an integral unit 
with eight catalytic sites. They include p-ketoacyl synthase (KS), malonyl (MT) / acetyl 
transferase (AT), dehydratase (DE), enoyl reductase (ER), p-ketoacyl reductase (KR), 
acyl carrier protein (ACP) and thioesterase (TE). In order to be activated, FAS situates 
two monomers head-to-tail to form a homodimer with the molecular size of around 250 
kDa. (Menendez et al, 2004b) (Fig. 1.1) 
2 
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Mammalian Fatty Acid Synthase 
K S “如.丨 -AC—④ I ^ ^ ^ 
；! 0 一 ‘ 
K R — ^ ^ ^ ： | ^ . ； ： ： ； 
<&K. rasrtk m? 
Fig. 1.1 Diagram showing a homodimer of animal FAS with seven catalytic domains 
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1.2 Fatty Acid biosynthesis reactions 
De novo fatty acid biosynthesis involves a series of carboxylation, transacylation, 
elimination and reduction reactions，in which the condensation occurs between 
malonyl-CoA and acetyl-CoA to form end-product palmitate. In order to synthesize 
palmitate, the first and the most crucial reaction is to produce malonyl-CoA from 
endogenous acetyl-CoA. This reaction is a physiologically irreversible and 
rate-determining step which involves activation of acetyl-CoA, by the addition of a 
carbon dioxide under the action of Acetyl-CoA carboxylase (Fig 1.2) 
ATP ADP + p. 
II II 
CH3-C—SCdA + HCO - — — ^ ^ — — ^ .OOC—CH2-C—SCoA 
^ 加 血 Malonyl-CoA 
Fig. 1.2 Rate-determining step ofde novo mammalian fatty acid synthesis 
Then, Acetyl-CoA:ACP transacylase takes away an acetyl group from Acetyl-CoA 
in exchange for ACP to form Acetyl-ACP (STEP 1) (Fig. 1.3 and 1.4). Under action of 
p-ketoacyl-ACP synthase, Acetyl-ACP forms complex with enzyme to form 
acetyl-enzyme (STEP 2a). On the other hand, Malonyl-CoA:ACP transacylase enables the 
malonyl group to leave away from Malonyl-CoA and bond with SACP to form 
malonyl-SACP (STEP 2b) which incorporated into acetyl-enzyme to generate 
acetoacetyl-ACP (STEP 3). Now the carbon dioxide leaves the malonyl group, with the 
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electrons from its bond attacking the acyl group of Acetyl-ACP complex, generating a 
P-ketoacyl group ready to go through the reverse of the reactions of p-oxidation. 
The keto-group of acetoacetyl-ACP is reduced to an alcohol using NADPH 
(b-ketoacyl-ACP reductase) (STEP 4), followed by the elimination of the alcohol 
(Enoyl-ACP hydrase) (STEP 5) to generate the cz5-2,3-enoyl group. The enoyl is then 
reduced with NADPH substituting for FADH2 (Enoyl-ACP reductase) to give the 
saturated 4-carbon butyryl-ACP (STEP 6). Then, the cycle repeats by shunting the reaction 
back to step 2a, although now the starting material has two additional carbon units than in 
the previous cycle. (Smith et al” 2003) 
After seven turns of the cycle, a 16-carbon palmitoyl-enzyme complex is formed, of 
which the ACP group is removed by palmityol thioesterase (STEP 7), forming palmitate as 
the predominant product of de novo FAS synthesis. Palmitate can then be utilized for 
lipogenesis in cells to make membrane-bounded structures, like plasma membrane, ER 
and Golgi apparatus, which has high turnover rate in lipogenic tissues or rapid-dividing 
tumor cells. 
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OH 〇 
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H T o / H o 
Butyryl-ACP C H s - i - O H ^ - c ' - ^ C P / 
A A i 
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(coTid^nsing e j i ^ m ) r H—SACP 
H O 
Butyiyl-enzyme CH3 —(!：—CHj—C—SE J 
^ et cetera, recycling reactions 2-6 six more times r PaseSc, 1997 
Fig. 1.3 Reaction sequence for biosynthesis of fatty acids de novo by the animal FAS 
Acetyl-CoA + 7 malonyl-CoA +14 NADH 
今 palmitate + 7 CO2 + 14 NAD+ + 8 CoA 
Fig. 1.4 Overall equation for the de novo synthesis of palmitate from acetyl CoA 
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1.3 Malonyl Coenzyme A - An important mediator in lipogenesis 
It was reported that substrate accumulation from FAS inhibition was responsible for 
cytotoxicity in breast (Zhou et aL, 2003) and ovarian cancer (Zhou et al, 2007). Though 
supplement of exogenous FAS end-product palmitate could reverse 
FAS-inhibition-induced cytotoxicity in leukemia (Pizer et al., 1996c)，breast (Menendez 
et al, 2004g) and prostate cancers (Brusselmans et al” 2005a), more studies have shown 
that malonyl-CoA seems to be a more crucial target to mediate cytotoxicity by FAS 
inhibition in tumor cells. Pharmacological inhibition of FAS accumulated malonyl-CoA 
to trigger apoptosis in breast cancer cells (Thupari et al., 2001 & 2002). In meanwhile, 
blockade of FAS mRNA expression by small interfering RNA in breast cancer cells also 
caused accumulation of malonyl-CoA and elevated levels of the proapoptotic genes 
BNIP3, TRAIL, and DAPK2, resulting in apoptosis (Bandyopadhyay et al., 2006). In 
addition, administering 5 -(tetradecyloxy)-2-furoic acid (TOFA)，an inhibitor of 
acetyl-CoA carboxylase to relieve malonyl-CoA accumulation reduced the cytotoxicity 
by FAS inhibition in breast cancer cells (Pizer et al., 2000). 
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1.4 FAS expression in different histotypes 
1.4.1 FAS in normal cells 
FAS is expressed at low to even undetectable levels in most normal human tissues, 
yet FAS-dependent fatty acid synthase still functions crucially in highly lipopgenic 
tissues, for instance: liver, lactating breast and adipose tissues. FAS is responsible for (1) 
storage of excess energy intake, e.g. fat, (2) synthesis of fat from other carbohydrate or 
protein sources once the diet is low in fat, (3) synthesis of fat for lactation of the pregnant. 
In well-nourish and healthy adults, FAS works primarily for energy storage by converting 
excess carbohydrate to fatty acids which are then stored as triacylglycerols. Specialized 
physiological functions include milk lipid production in lactating breast tissues as well as 
surfactant in infant lungs (Menendez et al, 2004b). 
L4.2 FAS in pathological cells 
Hereditary gingival fibromatosis (HGF) is a genetic disease of a progressive 
enlargement of the gingival. Recent researches showed that FAS was expressed by 
gingival fibroblasts and highly expressed in proliferative HGF cells. Moreover, FAS 
inhibition significantly reduced both normal gingiva and HGF fibroblast growth, 
indicating that androgen-driven fatty acid biosynthesis takes part in their proliferation. 
(Almeida et al., 2005) 
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Paget's disease is a malfunction of bone remodeling, in which bone breaks down 
more quickly, and when it grows again，softer than normal bone. Paget's disease 
diversely affects many bone structures, like the skull, the hip and pelvis and bones in the 
legs and back. Clinical studies showed that increased FAS expression was observed in 
87% of patients with invasive Paget's disease of the vulva (PDV) and 75% with 
microinvasive PDV. Statistical analysis revealed that FAS over-expression was highly 
associated with invasive PDV (Alo et ai, 2005). 
1.4.3 Tumor-associated FAS (Oncogenic antigen-519) in cancer cells 
Over-expression and hyperactivity of FAS have been characterized in various 
human malignancies, including carcinoma of breast (Alo et al, 1996), ovary (Gansler et 
al., 1997), oral tongue (Krontiras et al, 1999), colorectum (Visca et al, 1999), lung 
(Piyathilake et al., 2000), prostate (Bull et al,, 2001), oesophagus (nemoto et al, 2001)， 
stomach (Kusakabe et al, 2002)，skin (Innocenzi et al., 2003) and bladder (Visca et al., 
2003), with low expression levels in normal tissues. 
Increased FAS expression closely correlates malignancy of cancer. In the animal 
model, high FAS expression and activity in transgenic adenocarcinoma of mouse prostate 
(TRAMP) increased with age, tumor progression, and in metastatic lesions. (Pflug et al., 
2003). Immunohistochemical studies illustrated that expression of fatty acid synthase was 
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Stronger in malignant melanomas in comparison to conventional nevi and Spitz nevi, and 
was the highest for metastatic melanoma (Kapur et al., 2005). Yang et al (2002) also 
claimed of the need of FAS activation during neoplasmic lipogenesis and transformation 
from epithelial cells into metastatic cancer cells. Epstein-Barr virus (EBV) is a human 
gamma-herpes virus found associated with a variety of cancers, including Burkitt's 
lymphoma, nasopharyngeal carcinoma, gastric carcinoma. It was also found that FAS 
expression was significantly induced by the Epstein-Barr virus immediate-early protein 
BRLFl and was required for lytic viral gene expression (Li et al” 2004). FAS works 
closely with EBV to trigger malignancy of several cancer types. 
Increased FAS expression also correlates with poor prognosis and survival. 
Statistical analysis revealed that FAS-positive lung cancer patients had an overall lower 
prognostic value while FAS-negative expression in stage I patients had better survival. 
FAS seemed to be a marker of increased risk of recurrence in lung carcinoma (Visca et 
al, 2004). 
Availability of fatty acids may modulate proliferation of FAS-overexpressing 
cancer cells either by (1) supplying a larger pool of available substrates for membrane 
synthesis in rapid cell division or (2) by regulating membranous second messengers 
required for cell replication. (Baron et al., 2004) Essential fatty acids are not only 
energy-rich molecules, but also an important component of the membrane bilayer. A 
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report showed that arachidonic acid (an omega-6 fatty acid) played an important role in 
stimulation of growth-related genes and proliferation, via PI3K signaling and NF-kappaB 
translocation to the nucleus in PC-3 human prostate cancer cells. (Hughes-Fulford et al, 
2006). This may indicate the importance of fatty acids in cancer development. 
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1.5 FAS signaling models in breast and prostate cancers 
1.5.1 Association between FAS and PI3K/Aktpathway 
FAS over-expression and hyperactivity were highly associated with PI3K/Akt 
pathway (Fig 1.5). In LNCaP prostate carcinoma, administering LY294002, an inhibitor 
of the PI3K pathway, caused a dramatic decrease in FAS protein expression. 
Reintroduction of PTEN，a negative PI3K regulator, resulted in decreased levels of FAS 
expression which was dependent on its lipid phosphatase activity (Van de Sande et al, 
2002). Likewise, inhibition of PI3K pathway in prostate cancer worked synergistically 
with FAS siRNA to enhance cell death (Bandyopadhyay et al, 2005). Recent studies 
revealed that high-level expression of fatty acid synthase was linked to activation and 
nuclear localization of Akt/PKB by envision detection technique on well-preserved 
frozen prostate needle biopsies (Van de Sande et al., 2005). In addition, positive feedback 
regulation between AKT activation and fatty acid synthase expression was found in 
ovarian carcinoma cells (Wang et al, 2005). 
Although novel studies have indicated the possible role of MAPK/Erk pathway in 
fatty acid biosynthesis, the conclusion is inconsistent (Yang et al, 2002) (Menendez et al, 
2004(1) and it probably needs further elucidation of the mechanism behind. 
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1.5.2 Hypothetical model of FAS hyperactivity in breast and prostate cancer cells 
Different hypothetical models of FAS regulation has been proposed for normal and 
cancer cells. In normal lipogenic cells like hepatocytes and adipocytes, FAS-catalyzed de 
novo fatty acid biosynthesis is nutrient-dependent. FAS activity can be stimulated by a 
high carbohydrate diet, and inhibited by dietary fatty acid or during fasting. Hormones, 
like insulin, leptin, also take part in regulation of FAS expression via modulation of the 
transcriptional factor sterol regulatory element-binding protein (SREBP)-lc and MAPK 
ERKl/2 and PI-S'K/AKT signaling cascades. (Menendez et al, 2004d) 
Nevertheless, in breast and prostate cancer cells, SREBP-lc expression is driven 
by pathological conditions, like overexpression of growth factors (e.g. EGF, heregulin), 
and/or overexpression of growth factor receptors (e.g. Her-2/neu, EGFR), leading to 
hyperactivation of PI3k/Akt pathway, rather than responding normally to physiological 
regulators (e.g. insulin, leptin) as in normal lipogenic cells. The constitutive activation of 
oncogenic cascades would then hinder FAS gene to respond to a normal fatty acid's 
down-regulatory actions, and with a positive feedback loop, thus resulting in the observed 
gigantic levels of FAS in cancer cells (Menendez et al, 2004b) (Fig. 1.6). 
13 
Chapter 1 
' 「 4 ' X ‘ z / ^^JL^ / I I 
^^^ / J 
Protein synthesis ^ / j 
: 厂 - V I … 、 ‘ \ 
\ l ' ‘ 、 Transcription \ 
:丨:… . : ,�:: .:丨:I V Transcription 
Proliferation \ | 
Apoptosis, cell-cycle arrest 
(Van de Sande et al., 2002) 
Fig. 1.5 Phosphatidylinositol 3-kinase (PI3K) signaling pathway 
E絮 0 EGFR Her-2/neu 广 ^ 
i ^ ^ A 谢 3 
SREBP.1C ® ) 
•HZZZZZ] 
CANCER CELLS , • 、 
(Menendez et al., 2004b) 
Fig. 1.6 Proposed FAS regulatory positive-feedback loop in breast and prostate cancer cells 
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1.6 FAS inhibition to tackle cancer cell growth 
1.6.1 FAS inhibitors 
Apart from obesity treatment studies by using FAS inhibitors (Thupari et cd., 
2002) (Leonhardt & Langhans, 2004)，researches in the recent few years focus on the 
anti-cancer effect of FAS inhibition on growth of different cancer histotypes. With 
head-to-tail dimer conformation, targeted inhibition of one of the enzymatic domains of 
FAS can block the activity of one or both FAS subunits. 
Specific inhibitors investigated nowadays include cerulenin and C75, with 
triclosan and orlistat recently discovered with anti-tumor activity (Kridel et al.，2004) 
(Russell, 2004). Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro 
and exert cytotoxic effect to MCF-7 and SKBr-3 breast cancer cells. (Liu et al., 2002) 
Orlistat (Xenicaltrade mark), a US Food and Drug Administration (FDA)-approved drug 
for bodyweight loss, has been demonstrated to act against breast cancer by blockade of 
cell cycle progression, promotion of apoptosis and PEA3-mediated transcriptional 
repression of Hev2/neu (erbB-2) oncogene. (Menendez et aL, 2005 e & f) Nevertheless, 
researches on these two inhibitors are just preliminary and the underlying mechanisms of 
action have been merely on start. On the other hand, cerulenin and C75 are the two 
inhibitors recognized and studied for decade. 
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1.6.1.1 Cerulenin 
Cerulenin [(2R,3S), 2-3-epoxy-4-oxo-7,10-trans,transdodecadienamide] is an 
mycotoxin discovered by Hata et al. in 1960 from fungus Cephalosporium caerulens 
(Omura, 1976). Cerulenin is a natural specific noncompetitive inhibitor of the P-ketoacyl 
synthase activity of FAS, functions by covalently modifying the active site cysteine, 
resulting in dead-end FAS inhibition (Menendez et al., 2004b) (Fig. 1.5). 
It was found that cerulenin induced apoptosis in different wild-type p53 and mutant 
p53 tumor cell lines in vitro, through accumulation of tumor suppressor p53, 
up-regulation of apoptotic Bax protein, activation of caspases 3 and 9，as well as 
accompanied by release of cytochrome c from mitochondria. In contrast, normal human 
keratinocytes and fibroblasts were resistant to the apoptotic effect by cerulenin (Heiligtag 
et al., 2002). In addition, in vivo studies showed that fatty acid synthesis inhibition 
delayed tumor progression in a xenograft model of ovarian cancer. Cerulenin 
significantly hindered tumor cell fatty acid biosynthesis in vivo, ablated established 
ascites tumor, attenuated ascites incidence, delayed onset of ascites and markedly 
increased survival (Pizer et al, 1996b). 
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1.6.1.2 C75 
CIS [4-methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylic acid], a synthetic 
analog of cerulenin, is a a-methylene-butyrolactone inhibitor of FAS (Fig. 1.7). 
Treated with C75, subcutaneous xenografts of MCF-7 breast carcinoma in nude mice 
showed significant fatty acid synthesis inhibition, apoptosis, and tumor growth inhibition 
to less than 1/8 of control volumes, without comparable toxicity in normal tissues (Pizer 
et al., 2000). It was also found that C75 caused marked delay in tumor progression in 
neu-'H transgenic mice of mammary cancer (Ali i et al., 2005). 
1.6.2 Small interfering RNA 
Apart from post-translational modification of FAS, FAS hyperactivity and 
over-expression can also be down-regulated by small interference RNA technique in 
which translation of cytosolic FAS mRNA is blocked by enzymatic degradation. It was 
reported that RNA interference-mediated silencing of the FAS gene reduced growth and 
induced morphological changes and apoptosis of LNCaP prostate cancer cells (De 
Schrijver et al.’ 2003). On the other hand, silencing of the ACC-alpha gene, the enzyme 
which provides the malonyl-CoA substrate, also resulted in cell growth inhibition and 
induction of caspase-mediated apoptosis in highly lipogenic LNCaP prostate cancer cells 
as similarly as when treated with FAS RNAi (Brusselmans et al., 2005a). 
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Fig. 1.7 Pharmacological FAS inhibitors used in biological research nowadays. 
(a) Molecular structures of cerulenin, C75, triclosan and orlistat, (b) FAS inhibitors 
cerulenin and C75 act on different catalytic domains of FAS homodimer 
18 
‘ Chapter 3 
1.7 FAS inhibition to enhance chemoresistant cancer cells sensitivity to drugs 
Chemotherapeutic anti-cancer drugs always poses harmful side effects on normal 
cells. Toxicity of taxol always bring bone marrow suppression (principally neutropenia), 
alopecia, and hypersensitivity reactions to cancer patients (Markman，2002), while 
vinorelbine triggers febrile neutropenia including, neurotoxicity and thrombocytopenia 
(Crown et al, 2002). Monotherapy of recently-developed drug trastuzumab on Her2/neu 
overexpressing breast cancer patients also induced cardiac dysfunction (Campone et al., 
2004). 
Apart from killing cancer cells directly，blockage of FAS expression potentiates 
sensitivity of chemoresistant cancer cells towards these anti-cancer therapeutic drugs. 
Pharmacological and small interference RNA-mediated inhibition of breast 
cancer-associated fatty acid synthase synergistically enhances Taxol (Paclitaxel)-induced 
cytotoxicity, alleviating possible side effects when drugs were applied alone (Menendez 
et al, 2005d). FAS activity blockade by cerulenin and C75 was also found synergistically 
enhance apoptosis-inducing activity of vinorelbine in MCF-7, MDA-MB-231 and 
SK-BR-3 breast cancer cells (Menendez et al,, 2004a). Likewise, the dual targeting of 
FAS and HER2 by specific chemical FAS inhibitors and the humanized antibody 
trastuzumab (Herceptin) which directed against HER2, were synergistically cytotoxic 
towards HER2-overexpressing breast carcinoma (Menendez et al., 2004h). 
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1.8 Hypothesis 
FAS has been the molecular target for anticancer therapy, but still, most of the 
studies of FAS inhibition mainly focused on FAS-overexpressing breast and prostate 
cancer. Though various cancer histotypes highly expressed FAS, and they were reported 
to induce programmed cell death by pharmacological FAS inhibitors or small interference 
RNA, the detailed molecular pathway of such suicidal cell death was not fully elucidated. 
We aim to screen through a panel of different cancer cell lines to choose the most 
sensitive one as the cell line model, then investigating exactly how FAS inhibition 
modulates signaling cascades and finally causing programmed cell death in cancer cells. 
Identification of such signaling cascades provides more information on targeting FAS, 
and probably develops synergy with other chemotherapeutic agents, to cure cancer 
patients in the near future. 
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CHAPTER 2 Materials and Methods 
2.1 Chemicals and antibodies 
Cerulenin, CIS and all other chemicals used in this study were obtained from Sigma 
Chemcial (St. Louis, MO), unless otherwise stated. Mouse anti-human P-actin and DR4, 
DR5, TRAIL, Bax, fatty acid synthase antibodies were obtained from BD PharMingen. 
Other antibodies were obtained from Cell Signaling Technology (Danvers，MA). 
2.2 Cell cultures 
Hepatocellular carcinoma HepG2, melanoma A-375, lung carcinoma A-549, 
colorectal adenocarcinoma CaCo-2, Colo201, SW480 and SW620, cervix 
adenocarcinoma HeLa, prostate carcinoma LNCaP and PC-3, breast adenocarcinoma 
MCF-7 and SK-BR-3, and normal fibroblast HS68 were all provided by American Type 
Culture Collection (Rockville, MD). MCF-7, HepG2 and HS68 were cultured in RPMI 
1640 medium, PC-3 and A-549 in F12K medium, A-375 and CaCo-2 in DMEM medium, 
SW480 and SW620 in L I5 medium, HeLa in DMEM, SK-BR-3 in McCoy's 5a medium, 
LNCaP in the RPMI medium with 4g/L glucose. Al l the cultures were supplemented with 
0.25% sodium bicarbonate, 10% heat-inactivated fetal bovine serum (FBS) (HyClone, 
Logan, UT) and 2% penicillin-streptomycin (Gibco, Rockville, MD); and were incubated 
at 95% relative humidity, 5% CO2 and 37°C. The cultures were passaged at least three 
times a week. 
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2.3 MTT assay 
Cancer cells were seeded in 96-well flat-bottom plates at 2.5 x 10^ per well for 24 h. 
The cells were then incubated with cerulenin or CIS at 20，40 and 80 |j,M for 24 and 48 h. 
After incubation, cell proliferation and viability was measured by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based assay 
(Roche, Mannheim, Germany) (Loo and Rillema，1998). Twenty microliters of MTT 
solution (5 mg/ml in PBS) was added to the cells for 4 h at 37°C in CO2 incubator. The 
formazan salt formed was then dissolved by DMSO. Color intensity of the fomiazan 
solution, which reflects the cell growth condition, was determined by reading optical 
density at 570 nm by a microplate reader. Reductions of cell growth were plotted against 
cerulenin or CIS concentrations, and the value of IC50, i.e. the concentration at which the 
cell growth was inhibited by 50% of the control level, was estimated from the plot. 
2.4 5-Bromo-2'-deoxyuridme (BrdU)-labeling cell proliferation assay 
Cancer cells were seeded in 96-well flat-bottom plates at 2.5 x 10^ per well for 24 h. 
The cells were then incubated with cerulenin or CIS at 20，40 and 80 | iM for 24 and 48 h. 
A l l the procedures, including BrdU incorporation, fixation, washing and measurement 
were followed exactly as those described in the user's guide, distributed with the cell 
proliferation ELISA, BrdU (Chemiluminescence) kit from Roche, Mannheim, Germany. 
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2.5 Cytotoxicity detection assay of LDH release 
Human melanoma A-375 cells, in parallel with human normal fibroblast HS68 cells 
were seeded in the 96-well flat-bottom plates at 2.5 x 10^  and 5x 1respectively per 
well overnight. The cells were then incubated with cerulenin or C75 at 20, 40 and 80 |_iM 
for 24 h. After incubation, cell cytotoxicity was measured by the LDH detection assay 
(Roche, Mannheim, Germany). 2% Trizol Reagent (Invitrogen) was used to permeabilize 
all the cell membrane and acted as the high control. Reagent mixtures (according to 
user's guide) were added to the cells for 1 h at 37°C in CO2 incubator. Active LDH 
released from dead and plasma membrane-damaged cells, which was indicated by 
conversion of a yellow tetrazolium salt into a red, formazan-class dye, was then measured 
at 490 run by a microplate reader. LDH release was expressed as fold increase with the 
control. 
2.6 DNA flow cytometry 
Human melanoma A-375 cells, at number 5 x 10 ,^ were seeded in T25 culture flask 
for 24 h. The cells were then treated with 20, 40 and 80 | iM of cerulenin or CIS for 24 h. 
After incubation, the cells were trypsinized，washed with PBS and fixed overnight in 
ice-cold 70% ethanol. After fixation, the cells were washed twice with 1% BSA in PBS, 
resuspended in 1 ml DNA-binding propidium iodide (PI) solution (10 mg/ml in PBS, 
containing 0.05 mg/ml RNase A) and analyzed with EPICS XL flow cytometer (Beckman 
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Coulter, Miami, FL). Cell cycle was analyzed using MultiCycle software (Phoenix Flow 
Systems, San Diego, CA). SubGi or apoptotic cells and cells with different phases in cell 
cycle were measured using the control software of flow cytometer. 
2.7 Confocal micocropy 
Human melanoma A-375 cells, at number 1 x lO* per 200 )j,l of medium, were 
seeded in each chamber of the 8-chamber polystyrene vessel tissue culture treated glass 
slide (Becton Dickinson, NJ, USA) and incubated for 24 h at 37°C in CO2 incubator. The 
cells were then incubated with cerulenin or C75 at 20，40 and 80 jLiM for 24 h. The vessel 
and the silicon borders were then removed, and the slide was rinsed with PBS and stained 
with 100 \x\ of Annexin-V-FLUOS Labeling Solution (Roche, Mannheim, Germany) for 
20 minutes at 37°C in CO2 incubator. The slide was then analyzed by the Bio-Rad 
Radiance 2100 MP Scanning System equipped with 488mn argon laser (Hertfordshire, 
England). Green fluorescence from fluorescein (FITC) on apoptotic cells and red 
fluorescence from propidium iodide (PI) in necrotic cells were measured at 518 nm and 
617 nm, respectively. 
2.8 Immunoblot analysis 
2.8.1 Preparation of protein lysates 
For preparation of total protein lysates，cells with different treatment, were harvested 
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and suspended for 2 h on ice in an extraction buffer (20 mM Tris-HCl at pH 8.0, 150 mM 
NaCl，5 mM EDTA，0.2% BSA，1% Triton X-100) supplemented with protease inhibitors 
(BD Biosciences, San Jose, CA). Lysates were obtained by centrifugation at 4 � C for 10 
minutes at 13 000 g. The resulting supematants were stored at -20 °C or used immediately. 
Aliquots of the supematants were used for protein concentration determination by the 
standard bicinchoninic acid assay kit (Pierce, Rockford, IL). 
To obtain mitochondrial and cytosolic fractions, homogenates from melanoma cells 
were fractionated by the Cytosol-Mitochondria Fractionation kit (Calbiochem). Briefly，1 
X 10^ cells were harvested and resuspended in cytosol extraction buffer supplemented 
with protease inhibitors for 15 minutes on ice, and disrupted using a Dounce homogenizer. 
Homogenates were then centrifuged at 700g at 4 °C for 10 minutes. The supematants 
were further centrifuged at 10 OOOg for 30 minutes at 4 °C. The resulting supematants 
(cytosolic fraction) and pellets (mitochondrial fraction) were stored at -20 °C or used 
immediately. 
2.8.2 Immunoblotting 
50 jag protein content of the cell lysate from different treatment was resolved by 
10% SDS-polyacrylamide gel. The proteins were then transferred to a nitrocellulose 
membrane (Amersham Life Science, Buckinghamshire, UK). The membrane was firstly 
blocked with 5% non-fat milk in TBS and 0.1% Tween 20 (Bio-Rad, Hercules, CA), and 
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then incubated with antibodies with agitation at 4°C overnight. P-Actin was also 
measured as loading control. After incubation, the membrane was washed by TBS and 
incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG 
polyclonal antibodies (Cell Signaling Technology) for 1 h with agitation at room 
temperature. Finally, the membrane was washed by TBS, incubated with 10 ml 
LumiGLO Substrate (Cell Signaling Technology), and then exposed to X-ray film. 
Antibodies were stripped from the membrane by 5 minute-wash of distilled water, 
followed by 5-minute-wash of 0.2 M sodium hydroxide solution and 10 minutes of 
distilled water wash, before blocked with 5% non-fat milk in TBS and 0.1% Tween 20 for 
re-probing of another antibody. 
2.9 Caspase inhibitor studies 
The melanoma cells were incubated with or without 100 )j,M of pan-caspase 
inhibitor Z-VAD-FMK, caspase-8 inhibitor (Z-IETD-FMK) and caspase-9 inhibitor 
(Z-LEHD-FMK) (BD PharMingen, Franklin Lakes, NJ) for 2 h. The cells were then 
treated with or without 40 [xM cerulenin or C75 for 24 h. After treatment, protein lysates 
were obtained and subjected to the PARP immunoblot analysis as described above. 
2.10 Analysis of mitochondrial membrane potential 
Loss of mitochondrial membrane potential (A中m) was detected by using the 
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potential-sensitive fluorescent probe, tetramethylrhodamine ethyl ester (TMRE; 
Molecular Probes, Eugene, OR). Treated or untreated cells were washed with PBS, then 
incubated with 25 nM TMRE for 15 minutes at 37 °C prior to analysis on a flow 
cytometer. As a positive control, cells were incubated with 100 j iM potential-disrupting 
agent, carbonyl cyanide 3-chlorophenylhydrazone (CCCP; Sigma) for 24 hours. Data are 
displayed as the percentage of cells with reduction in mitochondrial membrane potential. 
2.11 Determination of caspase activities 
Caspase-3 activities were determined by using the fluorogenic peptide substrates, 
DEVD-AMC (50 |iM) (Calbiochem). Cell lysates from 1 x 10^ cells and substrates were 
mixed in a standard reaction buffer (20 mM HEPES, 10% glycerol，2 mM dithiothreitol 
(DTT), pH 7.5), and incubated for 1 hour at 37 The amount of enzyme-catalyzed 
AMC release was measured by a fluorescence plate reader (Tecan, Grodig, Austria) with 
an excitation wavelength of 380 nm and an emission wavelength of 440 nm, and 
expressed as the fold increase to the control. 
2.12 siRNA transfection 
Individual siRNAs against the FAS gene were designed (sense sequences: 
CCCUGAGAUCCCAGCGCUGdTdT, antisense sequence: CAGCGCUCCCAUCUCAGGGdTdT) 
and custom synthesized by Dharmacon, Inc. (Lafayette, CO). SMARTpool siRNAs 
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synthesized by Dhannacon, Inc. were used for negative control. The siRNA was 
transfected into the melanoma cells using DharmaFECT 1 Transfection Reagent 
(Dharmacon, Lafayette, CO) according to the manufacturer's protocol. Protein lysates 
were obtained and subjected to immunoblot analysis as described above. 
2.13 Statistical analysis 
Results are expressed as mean 土 S.D. Means were compared by Student's r-test. n is 
the number of replicates for the experiment, p is the probability of random eiTor of the 
treatment group. * is denoted for p<0.05, meaning that the difference of the treatment 
group with the control is 95% due to the effect of the treatment while 5% due to random 
error, and is the confidence level generally accepted to claim as significantly different. ** 
is denoted for p<0.005 for very significantly different treatment group. 
28 
‘ Chapter 3 
Chapter 3 Results 
3.1 Cytostatic & cytotoxic studies of FAS inhibitors on human cancer cells 
3.1.1 Cerulenin and C75 suppress cell growth of different cancer histotypes 
Over-expression and hyperactivity of FAS have been characterized in various human 
malignancies. In order to test for the inhibitory effect of FAS inhibitors on growth of 
different cancer histotypes, a panel of cancer cell lines, including hepatocellular 
carcinoma HepG2, melanoma A-375, lung carcinoma A-549, colorectal adenocarcinoma 
CaCo-2, Colo201, SW480 and SW620, cervix adenocarcinoma HeLa, prostate carcinoma 
LNCaP and PC-3, and breast adenocarcinoma MCF-7 and SK-BR-3 were subjected to 10 
to 160 )j.M cerulenin and C75 treatment for 48 h. The cell proliferation and viability was 
then measured by MTT assay. 
3-(4,5-dimethylthiazol-2-yl)-2.5-dipheny 1 tetrazolium bromide (MTT)-based assay 
is a colorimetric assay measuring the reduction of a tetrazolium component MTT into a 
dark blue formazan by mitochondrial succinate dehydrogenase of viable cells. The 
number of viable cells is correlated to the amount of formazan formed. The assay 
revealed that both cerulenin and C75 inhibited proliferation and viability of all the tested 
cancer cell lines, with IC50 values ranging from 21.86 to 240.66 ^iM at 48 h of treatment 
(Table 3.1). Apart from colorectal Colo201, cerulenin was more potent than C75 in 
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suppressing growth of cancer cells. Amongst the 13 tested cell lines, lung carcinoma 
A-549 cells were the least susceptible to the growth inhibition by the two FAS inhibitors 
(cerulenin IC50 = 143.26 |iM; C75 IC50 = 240.66 |_iM). On the other hand, melanoma 
A-375 was found to be the most sensitive cancer cell line to the FAS inhibitors (cerulenin 
IC5o= 21.86 \iM; C75 IC5o= 32.43 |_iM). Further studies on the mechanisms of how the 
FAS inhibitors retarded cell growth were performed on A-375 cells. 
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Values of IC^。(piM) 
Cancer cell lines Histotypes cerulenin C75 
HepG2 Hepatocellular carcinoma 75.24 97.55 
A-375 Malignant melanoma 21.86 32.43 
A-549 Lung carcinoma 143.26 240.66 
CaCo-2 Colorectal adenocarcinoma 59.77 186.93 
Colo201 Colorectal adenocarcinoma* 52.57 38.33 
SW480 Colorectal adenocarcinoma 37.33 52.14 
SW620 Colorectal adenocarcinoma 27.75 45.91 
HeLa Cervix adenocarcinoma 85.74 79.11 
LNCaP Prostate carcinoma* 33.36 73.41 
PC-3 Prostate carcinoma* 30.18 67.86 
MCF-7 Breast adenocarcinoma* 47.61 84.05 
SK-BR-3 Breast adenocarcinoma* 42.43 78.78 
* Metatstatic histotypes 
Table 3.1 IC50 values of cerulenin and C75 on growth of cancer cell lines from 
different tissues at 48 h of treatment measured by the MTT-based 
assay. 
The cells were incubated with 10 - 160 [xM cerulenin or C75 for 48 h. 
Malignant melanoma A-375 had the lowest IC50 values among the cancer 
cell lines tested in this study. 
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3.1.2 Cerulenin and C75 suppress cell growth of A-3 75 dose- and time-dependently 
Human melanoma cell line A-375 was chosen for further mechanistic studies. To 
study the time effect of FAS inhibitors on cell growth and viability, A-375 was incubated 
with 20, 40 and 80 |_iM cerulenin or C75 for 24 and 48 h，by MTT-assay and 
BrdU-labeling assay. 
MTT-assay revealed that cerulenin have already retarded the cell proliferation and 
viability dose-dependently at 24 h (Fig. 3.1). The proliferation and viability was reduced 
by 20.78% to 61.71% of the control level by 20 to 80 ]iM cerulenin treatment. At 48 h, 
the growth inhibition was even more prominent so that the cell proliferation and viability 
was reduced by 54.09% to 83.43%. Similar time effect was also observed on C75 
treatment, although 20 [ iM of the inhibitor did not reduce the cell growth significantly. 
The cell proliferation and viability was reduced by 16.15% and 46.70% by 40 to 80 ^iM 
C75 respectively at 24 h. At 48 h, the growth was reduced by 44.28% and 75.58%. 
Overall speaking, C75 was less effective than cerulenin in suppressing the cell growth at 
both 24 and 48 h of treatment. 
To further evidence the inhibitory effect of the FAS inhibitors on melanoma A-375, 
5-Bromo-2'-deoxyuridine(BrdU)-labeling cell proliferation assay was employed to study 
specifically the effect of the FAS inhibitors on cell proliferation. BrdU-labeling assay 
measures the uptake of synthetic nucleoside thymidine analogue BrdU during DNA 
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synthesis, so that the more BrdU is found in the more actively-proliferating cells. The 
results showed that both cerulenin and CIS inhibited A-375 cell proliferation dose- and 
time-dependently (Fig. 3.2). At 24 h, the proliferation was reduced by 29.48% to 86.71% 
of the control level by cerulenin and by 19.62% to 47.03% by C75. At 48 h, the 
proliferation was more prominently reduced by 62.54% to 90.30% by cerulenin and by 
30.20% to 90.30% by CIS. 
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Fig. 3.1 Effect of FAS inhibitors on proliferation and viability of melanoma A-375 
cells measured by the MTT-based assay. 
The cells were incubated with 20 - 80 fj.M cerulenin or C75 for 24 h and 48 h. 
Both cerulenin and C75 reduced cell proliferation and viability, with the more 
prominent effect at 48 h of treatment. Results are expressed as mean 士 SD 
(n=4). **p<0.005, Student's Mest. 
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Fig. 3.2 Effect of FAS inhibitors on proliferation of melanoma A-375 cells 
measured by the BrdU-labeling assay. 
The cells were incubated with 20 - 80 |LIM cerulenin and C75 for 24 h and 48 h. 
Both cerulenin and C75 hindered proliferation of A-375 cells dose- and 
time-dependently. Results are expressed as mean 士 SD (n=4). *p<0.05; 
**p<0.005, Student's t-test. 
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3.1.3 Cerulenin and C75 exert cytotoxic effect on A-375 but not normal skin HS68 cells 
Protein lysates were prepared from melanoma A-375 and normal fibroblast HS68 
cells to compare their endogenous FAS level. The immunoblot showed that FAS was 
strongly expressed in A-375 but not HS68 cells (Fig. 3.3). 
Cytotoxicity effect of cerulenin and C75 was investigated on both A-375 and HS68 
cells with lactate dehydrogenase (LDH) cytotoxicity detection assay. LDH is a cytosolic 
enzyme that is released from the dead cells. Therefore, the higher the LDH level in the 
culture medium, the lower the cell viability and the higher the cytotoxicity of the tested 
sample. When the melanoma cells were treated with 20, 40 and 80 |_iM cerulenin or C75 
for 24 h，a dose-dependent increase of LDH release from the dead cells was found (Fig. 
3.4). On the contrary, the FAS inhibitors, especially C75, imposed much lesser toxicity on 
the normal fibroblast cells. It was noteworthy that although cerulenin was more effective 
than C75 in retarding growth of the melanoma cells, 80 |J.M of this inhibitor was also 
toxic to the normal skin cells after 24 h of treatment. 
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Fig. 3.3 Immunoblots of FAS expression in human melanoma A-375 and normal 
skin fibroblast HS68 cells. 
A-375 cells had a very much higher FAS expression level than HS68 cells. 
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Fig. 3.4 Differential cytotoxic effects of the FAS inhibitors on the viability of 
melanoma A-375 cells and normal skin fibroblast HS68 cells measured by 
the LDH release assay. 
The cells were treated with 20，40 and 80 \xM cerulenin or C75 for 24 h, and 
cytotoxicity of the FAS inhibitors was measured by LDH release assay. 
Although 80 ^ M cerulenin was toxic to both the melanoma and normal skin 
fibroblast, the FAS inhibitors exhibited very much lesser toxicity on the normal 
skin cells than the melanoma cells. Numeric data indicate fold of increase of 
LDH released from dead cells. Results are expressed as mean 土 SD (n=3). 
><0.05; **p<0.005, Student's Mest. 
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3.1.4 Cerulenin and C75 arrest cell cycle progression and induce apoptosis with DNA 
fragmentation 
DNA flow cytometry was used to investigate the effects of the FAS inhibitors on cell 
cycle and apoptosis in A-375 cells. Dose effect was first investigated by treating the cells 
with 20 - 80 }j.M of the inhibitor for 24 h. Representative DNA histograms and numeric 
data are shown in Figs. 3.5a and 3.5b respectively. At 24 h, cerulenin arrested cell cycle 
progression dose-dependently so that S phase cells increased by 118 to 135% of the 
control level at 20 to 80 |j.M of the inhibitor (Fig. 3.5b). This S phase arrest was 
accompanied by depletion of Gi cells. Although C75 is a synthetic analog of cerulenin, it 
affected the cell cycle differently and the effect seemed to be dependent on the dose 
applied. At 20 |_iM, C75 elevated Gi cells by 38.55% of the control level, with depletion 
of S cells; at 40 )LIM, the inhibitor increased S and G2/M cells, with decrease of Gi cells; 
and at 80 |iM, it elevated G2 cells prominently by 199.37%, with depletion of Gi cells 
(Fig. 3.5b). Besides arresting cell cycle progression, both cerulenin and C75 significantly 
induced DNA fragmentation, a hallmark of apoptosis, in the melanoma cells (Fig. 3.5a). 
At 80 |j.M, cerulenin and C75 elevated subGi or apoptotic cells by 5.35-fold and 8.71-fold 
of the control level, respectively (Fig. 3.5b). 
Time effect of the FAS inhibitor on inducing apoptosis was further investigated by 
treating the cells with 40 j iM of the inhibitor for 24 and 48 h. DNA fragmentation was 
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more prominent at 48 h drug treatment (Fig. 3.6a). At 40 |j,M cerulenin, proportion of 
subGi or apoptotic cells increased by 5.50-fold at 24 h and by 19.13-fold of the control 
level at 48 h. Likewise, 40 ^ M CIS elevated the apoptotic cells by 4.49- and 15.58-fold 
at 24 and 48 h respectively (Fig. 3.6b). 
Besides DNA flow cytometry, annexin V-FITC/PI staining and confocal microscopy 
were used to confirm the apoptotic effect of the FAS inhibitors. Apoptosis was triggered 
by cerulenin so that annexin V-FITC bound onto the melanoma cells and emitted green 
fluorescence (Fig. 3.7a). Although to lesser extents, cerulenin also induced necrosis so 
that PI penetrated into the cells and emitted red fluorescence (Fig. 3.7a). Similar 
observations were also found with the C75-treated cells (Fig 3.7b). Therefore, confocal 
microscopy studies illustrated that cerulenin and C75 induced apoptosis in A-375 cells. 
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Fig. 3.5 Dose-related effect of cerulenin and C75 on cell cycle progression and 
apoptosis in A-375 cells. 
The cells were treated with 20，40 and 80 |_iM cerulenin or C75 for 24 h，and 
were then subjected to DNA flow cytometry, (a) Representative DNA 
histograms showing that cerulenin and C75 accumulated cells at S and G2/M 
phases, respectively. Both cerulenin and CIS elevated subGi cells with 
fragmented DNA or apoptotic cells, (b) Numeric data showing proportion of 
cells in different cell cycle phases and apoptosis. Results are expressed as mean 
土 SD (n=3). V<0-05； **p<0.005，Student's /-test. 
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Fig. 3.6 Time-dependent induction of apoptosis induced by cerulenin and C75 on 
apoptosis in A-375 cells. 
The cells were treated with 40 |J.M cerulenin or C75 for 24 h and 48 h, which 
were then subjected to DNA flow cytometry, (a) Representative DNA 
histograms showing that both the FAS inhibitors elevated subGi cells with 
fragmented DNA or apoptotic cells time-dependently. (b) Numeric data 
showing proportion of cells in apoptosis. Results are expressed as mean 土 SD 
(n=3). *p<0.05; •*p<0.005, Student's Mest. 
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Fig. 3.7 Effects of cerulenin and C75 on apoptosis and necrosis in A-375 cells. 
The cells were treated with 20, 40 and 80 |LIM (a) cerulenin or (b) C75 for 24 h, 
followed by annexin V-FITC/PI staining and confocal microscopy. Green 
fluorescence was emitted from both necrotic and apoptotic cells while red 
fluorescence was emitted from necrotic cells. Both the FAS inhibitors induced 
apoptosis in the melanoma cells. 
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3.2 Mechanistic studies of FAS inhibitors in A-375 cells 
3.2.1 Cerulenin and C75 induce caspase-dependent apoptosis 
Caspase-3 is one of the key executioners of apoptotic cell death. Activation of 
caspase-3 requires cleavage of 35 kDa inactive zymogen procaspase-3 into small 
activated units and is the hallmark for caspase-dependent apoptosis. When HS68 cells 
were treated with 20，40 and 80 |LIM cerulenin or C75 for 24 h, no significant cleavage of 
procaspase-3 could be detected by immunoblot studies (Fig. 3.4). Cerulenin and C75 at 
least did not trigger caspase-dependent apoptosis on normal fibroblast HS68 cells. 
After treating with or without 20，40 and 80 f iM of cerulenin or C75 for 24 h, FAS, 
PARP and caspase-3 were determined in the melanoma cells with immunoblot analysis. 
Although both cerulenin and C75 seemed to deplete FAS expression, the magnitude of 
depletion was not very prominent (Fig. 3.8a). PARP involves in DNA repair to maintain 
cell viability in response to environmental stress, and cleavage of which causes cellular 
disassembly (Oliver et al., 1998). Caspase-3 may be activated during apoptosis and 
cleaves PARP (Fernandes-Alnemri et al., 1994). Both cerulenin and C75 induced 
cleavage of procaspase-3 (35 kDa) into its smaller active subimits (17 and 19 KDa) 
dose-dependently in A-375 cells (Fig. 3.8a). The caspase-3 activation was associated with 
cleavage of full length 116kDa PARP into its smaller inactive fragment (89 KDa). This 
PARP cleavage and inactivation also occurred dose-dependently (Fig. 3.8a). On the 
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contrary, both the FAS inhibitors did not induce caspase-3 activation in normal skin 
fibroblast HS68 (Fig. 3.8b)，suggesting that the caspase activation seemed to be specific 
in the melanoma cells. 
Caspase-3 activity assay was used to confirm the caspase activation by the FAS 
inhibitors. Compatible to the PARP study, the assay showed that caspase-3 activity was 
induced by cerulenin and C75 dose-dependently. Cerulenin significantly activated 
caspase-3 by 2.11-fold of the control level at 40 | iM and 5.70-fold at 80 i^M, while C75 
elevated the activity by 1.08-, 2.90- and 24.63-fold at 20, 40 and 80 \xM respectively (Fig. 
3.8c). Therefore, both the caspase-3 immunoblotting and activity assay showed that 
cerulenin- and C75-induced apoptosis involved caspase-3 activation. 
In addition to caspase-3，other downstream executioner caspases, including 
caspase-2, caspase-6 and caspase-7, might also play crucial roles in executing the FAS 
inhibitor-induced apoptosis. Immunoblots showed that both cerulenin and C75 induced 
proteolytic activation of all these executioner caspases (Fig. 3.9). Lamins, a substrate for 
activated caspase-6, was also cleaved into small fragment of 28 kDa, showing the caspase 
activation (Fig. 3.9). Cerulenin and C75 probably triggered caspase-dependent apoptosis, 
through activation of many downstream executioner caspase-2, 3，6, 7, to induce PARP 
and lamin a/c cleavage to cause DNA repair defect and nuclear membrane deformation, 
finally bringing the cells to the demise. To further confirm involvement of other caspases 
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in the induced apoptosis, the melanoma cells were pre-treated with 100 |_iM pan-caspase 
inhibitor Z-VAD-FMK for 2 H，followed by the cerulenin or CIS treatment at 40 |J,M for 
24 h. The caspase inhibitor completely rescued the cells from the PARP cleavage induced 
by cerulenin or C75 in immunoblot studies (Fig. 3.10a)，and the FAS inhibitor-induced 
growth inhibition in MTT assay (Fig. 3.10b)，suggesting that the apoptosis triggered by 
the FAS inhibitors was mediated by caspase activation. 
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Fig. 3.8 Induction of caspase-3 activation by cerulenin and C75 in A-375 cells. 
The cells were treated with 20，40 and 80 |LIM cerulenin or C75 for 24 h. (a) 
The melanoma A-375 cells did not show prominent change of FAS level after 
the treatment. However, both caspase-3 and PARP showed dose-dependent 
cleavage, suggesting that the FAS inhibitors might activate caspase-3 to cleave 
PARP. (b) The normal skin fibroblast HS68 did not show caspase-3 proteolytic 
cleavage after the treatment, (c) Both cerulenin and C75 induced 
dose-dependent elevation of caspase-3 activity. 
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Fig. 3.9 Induction of proteolytic activation of caspase-2, caspase-6, caspase-7 
and cleavage of lamin A/C by cerulenin and C75 in A-375 cells. 
The cells were treated with 20，40 and 80 \xM cerulenin or C75 for 24 h. 
The FAS inhibitors induced proteolysis and thus activation of the 
executioner caspases. Lamin A/C, a substrate of the activated caspase-6 
was also found to be cleared, suggesting that the caspase had been 
activated. 
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Fig. 3.10 Effect of pan-caspase inhibitor on cerulenin- and C75-induced PARP 
cleavage or growth inhibition in A-375 cells. 
The cells were pretreated with 100 |_iM pan-caspase inhibitor 
Z-VAD-FMK for 2 h before the cerulenin or C75 treatment, (a) The 
inhibitor completely rescued the cells from the FAS inhibitor-induced 
PARP cleavage in immunoblot studies, (b) the inhibitor rescued the cells 
from the FAS inhibitor-induced growth inhibition in MTT assay, 
suggesting that the apoptosis was solely caspase-dependent. 
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3.2.2 Cerulenin- and C75-induced apoptosis involve extrinsic death receptor pathway 
Apoptosis can be triggered by extrinsic signals (the death receptor pathway) and 
intrinsic signals (the mitochondrial pathway). The extrinsic death receptor pathway 
involves some external death ligands which bind to receptor domains on the membrane 
surface to activate the initiator caspases (e.g. caspase-8 and -10). The intrinsic 
mitochondrial pathway, on the other hand, involves the induced mitochondrial stress 
which releases apoptotic factors from mitochondria to the cytosol to activate another 
initiator caspase, i.e. caspase-9. Both the extrinsic and intrinsic apoptotic pathways 
finally convert their signals to activation of downstream executioner caspases responsible 
for DNA fragmentation. 
After treating with or without 20，40 and 80 [ iM cerulenin or C75 for 24 h, the 
molecules (Procaspase-8, -10，TRAIL, DR4 and DR5) in the death receptor apoptotic 
pathway were determined in the melanoma cells. Immunoblots showed that either 
cerulenin or C75 induced proteolytic processing of procaspase-8 dose-dependently (Fig. 
3.11). In comparison, procaspase-10 was only depleted at 80 \ iM cerulenin. Furthermore, 
the FAS inhibitors elevated death receptor DR5 level dose-dependently, but did not affect 
levels of death receptor DR4 and death ligand TRAIL. Using specific caspase-8 inhibitor, 
the crucial role of caspase-8 in the induced apoptosis was further confirmed (will be 
discussed later in section 3.2.3). 
52 
‘ Chapter 3 
To test the relation of elevated DR5 by the FAS inhibitors to activation of extrinsic 
apoptotic pathway, A-375 cells were at first treated with 10，20, 40 and 80 |_iM of 
cerulenin or C75 for 24 h, followed by administration of 12.5 ng/ml TRAIL molecules 12 
h prior to cell harvest. 12.5 ng/ml TRAIL molecules enhanced sensitivity of A-375 cells 
to apoptosis induced by 10 and 20 pJM of cerulenin, and 10, 20 and 40 |J,M of C75 (Fig. 
3.12). We therefore suggested that cerulenin and C75 triggered extrinsic apoptotic 
pathway by upregulating DR5 expression, which in turn activated proteolytic processing 
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Fig. 3.11 Immunoblots showing the effects of cerulenin and C75 on the 
molecules in the death receptor apoptotic signaling pathway in A-375 
cells. 
A-375 cells were treated with 20，40 and 80 j iM of cerulenin or C75 for 24 
h. Molecules in the death receptor pathway were then determined by 
immunoblot analysis. Either cerulenin or C75 induced proteolytic 
processing of procaspase-8 and elevation of DR5. 
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Fig. 3.12 Effect of TRAIL molecules on cerulenin- and C75-induced apoptosis 
on TRAIL-resistant A-375 cells. 
A-375 cells were treated with 10, 20, 40 and 80 |_iM of (a) cerulenin or (b) 
C75 for 24 h，with administration of 12.5 ng/ml TRAIL molecules 12 h 
prior to cell harvest. TRAIL molecules enhanced sensitivity of 
TRAIL-resistant A-375 cells to cerulenin- and C75-induced apoptosis. 
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Fig. 3.13 Immunoblots showing the effects of cerulenin and C75 on caspase-9. 
Cerulenin and C75 treatment triggered procaspase-9 cleavage at 40 and 80 
|j.M of cerulenin and C75 to switch on intrinsic apoptotic pathway. A-375 
cells were treated with 20，40 and 80 | iM of cerulenin or C75 for 24 h. 
Caspase-9 in the intrinsic mitochondrial apoptotic pathway was 
determined by immunoblotting. The zymogen (47 kDa) was cleaved into 
its active subunits (37 and 35 kDa) after treatment with the FAS inhibitors. 
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3 J. 3 Cerulenin- and C75-induced apoptosis involve intrinsic mitochondrial pathway 
Besides the extrinsic death receptor pathway, the mitochondrial apoptotic signaling 
molecules were also studied in the melanoma cells. After treatment with 20，40 and 80 
fj-M of cerulenin or CIS for 24 h, immunoblots showed that either cerulenin and C75 
triggered proteolytic processing of procaspase-9 so that it was cleaved into the active 
subunits (37 and 35 kDa) (Fig. 3.13). 
According to the current concept, upon firing of mitochondrial apoptotic signaling 
pathway, the mitochondrial membrane is first depolarized by the Bcl-2 family proteins so 
that apoptotic factor cytochrome c is released out of mitochondria. Cytochrome c then 
binds to procaspase-9/Apaf 1 complex in the cytosol for caspase-9 activation (Rodriguez 
and Lazebnik, 1999). To verify whether the caspase-9 activation was induced by 
mitochondrial depolarization, tetramethylrhodamine ethyl ester (TMRE) was employed 
as the probe for semi-quantitative measurement of mitochondrial membrane potential. 
When mitochondrial membrane depolarized, the cells are not able to uptake the probe so 
that the fluorescence peak in membrane potential histogram shifts to the left. Fig. 3.14 
shows a positive control with the emission peak shifted to the left by mitochondrial 
uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP). Upon FAS inhibitor 
treatment, mitochondrial membrane depolarization was observed. Cerulenin at 40 and 80 
I^M caused 15.51 % and 72.13 % of the cells to exhibit mitochondrial membrane 
depolarization (Fig. 3.14 a & b). Likewise, 10.17 % and 52.33 % of the cells were 
depolarized by 40 and 80 |aM C75，respectively. 
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Fig. 3.14 Representative histograms showing induction of mitochondrial 
depolarization by FAS inhibitors and CCCP. 
(a) mitochondrial depolarization was observed after cerulenin and CIS 
treatment on A-375 cells. Mitochondrial uncoupler carbonyl cyanide 
m-chlorophenylhydrazone (CCCP) was also included as the positive 
control, (b) Numeric data showing percentage of cells exhibiting 
mitochondrial depolarization. Results are expressed as mean 士 SD (n=3). 
*/7<0.05; **p<0.005, Student's Mest. 
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In conjunction with mitochondrial membrane depolarization, it was found from the 
immunoblot studies that apoptotic factors smac/Diablo and cytochrome c were released 
from mitochondria into the cytosol dose-dependently by the FAS inhibitors (Fig. 3.15). 
Cytochrome c binds to procaspase-9/Apaf 1 complex in cytosol to activate procaspase-9 
cleavage (Rodriguez and Lazebnik, 1999), while smac/Diablo interacts with the inhibitors 
of apoptosis protein (lAPs) to relieve their the inhibitory effect on caspases (Srinivasula 
et al., 2001). From the immunoblots in Fig. 3.16, both cerulenin and C75 induced 
depletion of lAP members XIAP and survivin. Therefore, the FAS inhibitors induced 
mitochondrial depolarization to release apoptotic factors and at the same time caused 
depletion of lAPs so that the caspases might be activated by them altogether. 
Mitochondrial membrane depolarization is regulated by the Bcl-2 protein family, in 
which pro-survival members (e.g. Bcl-2, Bcl-xL, Mcl - l ) antagonize pro-apoptotic 
proteins (e.g. Bax，Bim) and BH3-only proteins (e.g. Bad, Bmf) to produce a "net" 
death-promoting or death-suppressing cell fate. In this study, effects of the FAS inhibitors 
on some better-characterized Bcl-2 proteins were investigated. Fig. 3.17 showed that 
cerulenin and CIS caused depletion of anti-apoptotic members Bcl-xL at higher doses (40 
and 80 j iM) and Mcl - l at lower doses (20 and 40 \iM). However, no significant changes 
of the pro-apoptotic Bax and BH3 only proteins were observed. Our studies suggested 
that the FAS inhibitors might trigger the intrinsic mitochondrial apoptotic pathway in 
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Fig. 3.15 Immunoblots showing the effects of cerulenin and C75 on the 
mitochondrial and cytosolic levels of apoptotic factors Smac/Diablo 
and cytochrome c. 
The melanoma cells were treated with 20，40 and 80 j_iM cerulenin and 
C75 for 24 h. The cells were then lysed and subjected to 
mitochondrial/cytosolic fractionation. The fractions were then 
immunoblotted for the above apoptotic factors. Cerulenin and C75 caused 
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Fig. 3.16 Immunoblots showing the effects of cerulenin and C75 on levels of 
inhibitors of apoptosis protein (lAPs). 
The melanoma cells were treated with 20，40 and 80 j iM cerulenin and 
CIS for 24 h. Cerulenin and C75 induced depletion of XIAP and survivin 
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Fig. 3.17 Immunoblot showing the effects of cerulenin and C75 on the levels of 
the Bcl-2 family proteins in A-375 cells. 
The melanoma cells were treated with 20, 40 and 80 )j.M cerulenin and 
C75 for 24 h, and the levels of the Bcl-2 family proteins were measured by 
immunoblot analysis. The FAS inhibitors only depleted the level of 
anti-apoptotic Bcl-xL and Mcl-l and did not affect the level of other 
pro-apoptotic members. 
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A-375 cells at least by depleting level of the pro-survival Bcl-xL and Mcl- l , resulting in 
the net death-promoting effect to alter the mitochondrial membrane potential. Then, the 
mitochondrial membrane depolarization triggered the release of cytochrome c and 
smac/Diablo from mitochondria into the cytosol responsible for caspase-9 activation. In 
meanwhile, the FAS inhibitors also caused depletion of lAPs that favors the activation of 
downstream executioner caspases, resulting in DNA fragmentation of apoptosis. 
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3.2.4 Extrinsic death receptor pathway serves as a pioneer and links with intrinsic 
mitochondrial pathway in cerulenin- and C75-induced apoptosis 
Bid, the BH3 domain-only protein, is proteolytically cleaved by caspase-8 to 
truncated Bid which translocates to mitochondria to sensitize mitochondrial damage and 
cytochrome c release. Bid, therefore, relays extrinsic apoptotic signal from the cell 
surface to intrinsic apoptotic signal in mitochondria. From immunoblots in Fig. 3.18, it 
was found that cerulenin and C75 caused depletion of full size Bid (22kDa), possibly via 
cleavage by caspase-8, suggesting that a crosstalk might exist between the death receptor 
and mitochondrial apoptotic pathways in the induced apoptosis. 
Caspase inhibitor studies were then performed to find out which apoptotic pathway 
took the initiative in the cerulenin- and C75-induced apoptosis. Pre-treating the cells with 
pan-caspase inhibitor (Z-VAD-FMK) completely rescued them from having the PARP 
cleavage induced by the FAS inhibitor, indicating the induced apoptosis was solely 
caspase-dependent (Fig. 3.19). Furthermore，in the cerulenin-treated cells, caspase-8 
inhibitor (Z-IETD-FMK) completely rescued the cells from having PARP cleavage and 
caspase-9 inhibitor only partially reduced the cleavage level. In the C75-trteated cells, on 
the other hand, the caspase-8 inhibitor could not rescue the cells completely but was still 
more effective than the caspase-9 inhibitor. Therefore, both the Bid immunoblotting and 
caspase inhibitor studies supported that caspase-8 was the initiative caspase that might 
activate caspase-9, possibly through the Bid cleavage, and thus depleted its level. 
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Fig. 3.18 Immunoblots showing the effects of cerulenin and C75 on Bid. 
The melanoma cells were treated with 20, 40 and 80 jaM cerulenin and 
C75 for 24 h. Both the FAS inhibitors caused depletion of Bid protein and 
the depletion was more prominent and dose-dependent in the C75-treated 
cells. 
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Caspase Inhibitor Studies 
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Fig. 3.19 Immunoblot showing the effects of caspase inhibitors on cerulenin 
and C75-mduced PARP cleavage. 
The cells were first treated with 100 )J,M pan-caspase inhibitor 
(Z-VAD-FMK)，caspase-8 inhibitor (Z-IETD-FMK) or caspase-9 inhibitor 
(Z-LEHD-FMK) for 1 h, followed by incubation with 40 |iM cerulenin or 
C75 for 24 h. Pan-caspase inhibitor completely rescued the cells from 
having the FAS inhibitor-induced PARP cleavage. In the cerulenin-treated 
cells, caspase-8 inhibitor completely rescued the cells from having PARP 
cleavage as the pan-caspase inhibitor did. Caspase-9 inhibitor could only 
partially rescue the cells. In the C75-treated cells, both caspase-8 and 
caspase-9 inhibitors could only partially rescue the cells and caspase-8 
inhibitor was more effective. Therefore, caspase-8 seemed to be the 
initiative caspase in the induced apoptosis and might activate caspase-9. 
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3.3 Small interfering RNA on Fatty Acid Synthase (FAS siRNA) 
3.3.1 FAS SiRNA induces PARP cleavage 
To confirm the apoptosis in cerulenin- and C75-treated cells was due to the 
depletion of FAS activity, RNAi was used to knock down FAS expression temporarily 
inside the cells. To knock down FAS expression, A-375 cells were transfected with 100 or 
200 nM FAS siRNA for 72 h or 96 h. Immunoblots showed that the siRNA was effective 
to downregulate FAS expression at 72 h and there was a retrieval of the expression at 96 
h (Fig. 3.20). In meanwhile, the transfected cells also had PARP cleavage at 100 nM and 
200 nM siRNA after 72 h and 96 h of treatment (Fig. 3.20). Therefore, transfection with 
100 nM siRNA for 72 h was chosen for further studies. FAS siRNA probably induced 
apoptosis by reducing PARP level to hinder its role in DNA repair and so DNA 
fragmented for the cell to demise. 
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Fig. 3.20 Immunoblots showing the effects of FAS siRNA on FAS and PARP 
expression. 
The cells were treated with or without 100 or 200 nM FAS siRNA for 72 
or 96 h. The FAS expression was downregulated at 72 h but retrieved at 95 
h of treatment. PARP depletion was observed with FAS depletion. 
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J. 3.2 FAS siRNA triggers caspase-dependent apoptosis as FAS inhibitors 
When A-375 cells were transfected with 100 nM FAS siRNA for 72 h, 
downregulation of PARP was observed, which was associated with cleavage of 
procaspase-3, indicating the occurrence of apoptosis (Fig. 3.21). In the meanwhile, 
depletion of pro-caspase-8, procaspase-9 and Bid was also observed, which was similar 
to that found in the cerulenin- and C75-treated cells. Therefore, either pharmacological 
inhibition or molecular depletion of FAS resulted in apoptosis with similar molecular 
mechanism and activation of caspases in A-375 cells. 
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Fig. 3.21 Immunoblots showing the effects of FAS siRNA on several key 
molecules in apoptosis found in the FAS inhibitor studies. 
The cells were treated with or without 100 nM FAS siRNA for 72 h. FAS 
and several key molecules in the apoptotic pathway induced by cerulenin 
and C75 were then immunoblotted. The siRNA downregulated FAS 
expression and induced cleavage of procaspase-3 into its active fragments 
and of PARP, indicating the incidence of apoptosis. Similar to the 
apoptosis caused by the FAS inhibitors, depletion of procaspase-8, 
procaspase-9 and Bid was also found, suggesting that either 
pharmacological or molecular inhibition of FAS activity would lead to the 
apoptosis with similar molecular cascade. 
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CHAPTER 4 Discussion 
FAS inhibitors inhibited growth of various cancer cell lines in vitro. Huang et al. 
(2000b) demonstrated that cerulenin selectively exerted growth inhibitory effect on colonic 
cancer, but not on normal fibroblast. Likewise, Chen et al. (2000) showed that FAS 
inhibitors selectively inhibited proliferation of K562 leukemia cells dose-dependently. We 
found in this study that, besides colonic cancer and leukemia cells, FAS inhibitors 
cerulenin and C75 also inhibited the growth of cells from other cancers, including 
hepatocellular carcinoma, melanoma, lung carcinoma, colorectal adenocarcinoma, cervix 
adenocarcinoma, prostate carcinoma and breast adenocarcinoma (Table 3.1). Since 
melanoma A-375 was found to be the most sensitive cell line to the growth inhibition, it 
was used as the model to investigate the mechanism in the growth inhibition. 
Since FAS strongly expresses in melanoma A-375 but weakly expresses in normal 
skin fibroblast HS68 cells (Fig. 3.3), we speculated that the FAS inhibitors should have 
higher toxicity on the cancer than on the normal cells. We demonstrated that the FAS 
inhibitors, especially C75，was selectively cytotoxic to the melanoma cells (Fig 3.4). 
However, cerulenin was found in this study to be toxic to both A375 and HS68 cells at 80 
l_iM (-18 |j.g/ml). Previous studies also showed that cerulenin was harmless only at 
concentrations lower than 5 |ig/ml in gingival fibroblast (Zhang et al, 2005) and cervical 
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fibroblast (Pizer et al” 1996b). 
Several reports have shown that cerulenin has lower specificity than C75 as a fatty 
acid inhibitor, which may explain why cerulenin exerts toxicity on normal cells at high 
concentration. Cerulenin contains a very reactive epoxide group which interacts with 
proteins other than FAS. Cerulenin also inhibits protein palmitoylation, a process of 
posttranslational modification for key signaling proteins to attach to the plasma membrane 
(Jochen et al., 1995; Lawrence et al, 1999), which is more related to cancer cell growth 
inhibition than inhibition of FAS activity (Lawrence et al, 1999). Moreover, cerulenin 
hinders cholesterol synthesis (Goldfine et al, 1978; Malvoisin et al., 1990) and inhibits 
proteolysis (Ikuta et al.’ 1986; Moelling et al., 1990). In addition, the use of cerulenin as a 
FAS inhibitor is limited due to its chemical instability and more stable CIS has recently 
been developed (Kuhajda et al., 2000). 
Transformation of melanocytes to melanoma stems from abnormal changes in cell 
cycle regulatory mechanisms, including pRb and cyclin Di, which assist cell cycle phase 
transition, and negative regulators, like pi6，p27，p53 and p21, which cause cell cycle 
arrest (Lee and Yang, 2001; L i et al., 2006). Drugs that target these proteins and induce cell 
cycle arrest would be effective tools against melanoma development. Several reports have 
shown that FAS inhibitors retard cell growth by inducing cell cycle arrest. Orlistat blocked 
breast cancer cells at Gi/S checkpoint by downregulating E3 ligase Skp2 (Knowles et al, 
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2004). When treated with cerulenin and C75, RKO colon carcinoma cells exhibited a 
biphasic stress response with S phase and G2 arrest, resulting in delay of cell cycle 
progression (Li et al.，2001). Cerulenin elevated expression of cyclin-dependent kinase 
inhibitors p21 and p27, downregulated cyclin Di and arrested prostate cancer cells at G2/M 
phase (Furuya et al” 1997). C75 inhibited FAS activity and induced G2 phase arrest in 
HepG2 and SMMC7721 cells and triggered Gi phase arrest in Hep3B cells (Gao et al., 
2006). Moreover, time- and dose-dependent S phase arrest was found in glioma cells after 
cerulenin treatment (Zhao et al., 2006a). Other reports demonstrated that FAS inhibitors 
arrested cells at S phases in myeloma (Wang et al, 2006), leukemia and beast carcinoma 
(Pizer et al., 1998a). Likewise, our flow cytometric studies also showed that cerulenin and 
C75 redistributed the melanoma A375 cells into S and G2 phases, with significant depletion 
of Gi cells (Fig. 3.5), in parallel with dose-dependent reduction of cell growth. 
Pizer et al. (1998b) claimed a direct linkage between fatty acid synthesis and DNA 
synthesis in proliferating tumor cells. FAS inhibition actually deregulates adenine 
nucleotide biosynthesis, causing defect in DNA replication and nuclear division (Chung et 
al, 2006). Apart from DNA synthesis, Swinnen et al (2003) also suggested the importance 
of FAS overexpression to dysregulation of membrane composition in tumor cells. It was 
found that fatty acid synthase inhibition completely prevented lipid accumulation and 
hindered preadipocyte differentiation (Schmid et al., 2005). Cerulenin and C75 probably 
74 
‘ Chapter 3 
exert their growth-inhibitory effect via cell cycle arrest by interfering with the DNA 
replication machinery and deregulating different cell cycle phases. Cessation of rapid 
growth, lipogensis of tumor-associated cell membranes and proliferation that melanoma 
cells originally possessed is thus resulted. 
Apoptosis is a programmed cell death characterized by chromatin condensation, 
nucleosome-sized DNA fragments, membrane blebbing, cell shrinkage, and 
compartmentalization of the dead cells into membraneous apoptotic bodies (Darzynkiewicz 
et aL, 1997). Apoptosis brings homeostasis by maintaining optimum cell number in our 
body. Cells that are diseased, malfunctioning or under stress may undergo apoptosis and be 
replaced by healthy ones. Over the past few decades, apoptosis has been regarded as a 
novel target for cancer chemotherapy, and a variety of apoptosis pathway-targeted drugs 
are in clinical trials (Cummings et al, 2004). 
Cancer cell proliferation requires FAS overexpression since FAS synthesizes fatty 
acids for membraneous structures in rapidly-dividing cancer cells (Swinnen et al. 2003). 
FAS blockade by pharmacological inhibitors or small interfering RNA induce apoptosis in 
different cancer cells, including myeloma (Wang et al.’ 2006), glioma (Zhao et al., 2006a), 
oral squamous cell carcinoma (Zhang et cd., 2005)，pediatric medulloblastoma (Slade et al., 
2003), colonic carcinoma (Huang et al., 2000 a,c), leukemia (Chen et al, 2000) prostate 
(Furuya et al, 1997), breast (Pizer et al., 1996a) and endometrical cancers (Lupu et al, 
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2006), with PARP cleavage and DNA fragmentation. We are the pioneer group to show that 
cerulenin and CIS also triggered apoptosis in melanoma A375 cells, indicated by strong 
green florescent annexin V-FITC signal in confocal microscopy (Fig. 3.7), dose-dependent 
cleavage of downstream caspase-3 and PARP in immunoblotting (Fig. 3.8a)，and 
dose-dependent and time-dependent elevation of subGi cell proportion in DNA flow 
cytometry (Fig 3.5 & 3.6). Heiligtag et al (2002) demonstrated that cerulenin triggered 
mitochondrial apoptotic pathway with caspase-3 activation in a panel of wild-type p53 and 
mutant p53 tumor cell lines. We also showed in this study that administering pan-caspase 
inhibitor Z-VAD-FMK completely rescued cells from cerulenin- and C75-induced 
apoptosis, indicating such apoptosis is solely caspase-dependent (Fig. 3.10). Overall 
speaking, present and previous studies support that FAS pharmacological inhibitors retard 
cancer cell growth effectively and caspase-dependent apoptosis plays an important role to 
bring cells to demise. 
Apoptosis can be triggered by extrinsic signals (death receptor pathway) and intrinsic 
signals (mitochondrial pathway). Mitochondrial apoptotic pathway involves complex 
signaling cascades and is tightly regulated by the Bcl-2 family proteins in which different 
members promote or block cell death at different stages to control cell fate (Reed et al” 
1997). In mammalian cells, the Bcl-2 family could be divided into three groups upon their 
functions and sequence homology: the pro-survival Bcl-2 subfamily includes Bcl-2, Bcl-xL, 
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Mcl-l，Al and Bcl-w; the pro-apoptotic Bax subfamily includes Bax，Bak, and Bok; and 
the death-promoting BH3-only subfamily includes Bid, Bim，Bik，Bad, Bmf, Hrk，Noxa, 
and Puma (Zamzami and Kroemer, 2001). These molecules either homodimerize or 
heterodimerize with molecules of opposing functions, and the ratio of pro-apoptotic and 
anti-apoptotic proteins decides between cell survival and apoptosis. Mitochondria take a 
crucial role in apoptosis, and in case apoptosis occurs, the mitochondrial membrane wil l be 
depolarized and permeabilized to release apoptotic factors into cytosol to transducer the 
apoptotic cascades downstream (Kromer and Reed, 2000). Our TMRE studies indicated 
that both cerulenin and CIS induced the mitochondrial membrane depolarization in A375 
cells (Fig. 3.14). In meanwhile, apoptotic factors Smac/Diablo and cytochrome c were also 
found in the cytosol (Fig. 3.15). Al l these findings evidenced the initiation of the 
mitochondrial pathway by the FAS inhibitors. 
Previous reports have also shown that FAS inhibitors trigger the 
mitochondrial-mediated apoptosis in a variety of cancer cell lines, though with different 
Bcl-2 family proteins to trigger the depolarization. It was found that cerulenin caused 
apoptotic cell death and PARP cleavage in U251 and SNB-19 glioma cells independent of 
the death-receptor pathway, and overexpressing Bcl-2 inhibited the cell death (Zhao et al., 
2006a). In vitro studies on a panel of wild-type and mutant p53 cell lines have shown that 
the cerulenin-induced apoptosis associated with release of cytochrome c and cleavage of 
77 
‘ Chapter 3 
Bax (Heiligtag et al., 2002). Likewise, nude mice transplanted with colonic carcinoma 
LoVo cells showed elevation of Bax and reduction of Bcl-2 proteins after cerulenin 
administration (Huang et al., 2000a). 
With the immunoblots on the Bcl-2 family proteins in this study, we are the pioneer 
group to illustrate that FAS inhibitor significantly depletes Mcl- l and Bcl-xL proteins in 
the melanoma cells (Fig. 3.17). Mcl- l is anti-apoptotic, interacting with and antagonizing 
pro-apoptotic Bcl-2 members to maintain mitochondrial integrity and cell viability in 
cancer cells (Mandelin and Pope, 2007). Mcl- l is highly expressed to resist apoptosis in 
melanoma cells and has been regarded as a therapeutic target for melanoma since enhanced 
killing on melanoma existed by simultaneously targeting Mcl- l and Noxa (Qin et al； 
2006). Mcl- l antisense therapy also sensitized human melanoma in a SCID mouse 
xenotransplantation model (Thallinger et al, 2003). Anti-apoptotic Bcl-xL is to maintain 
metabolite exchange across the outer mitochondrial membrane under stress conditions, and 
malfunction of which causes membrane depolarization and apoptosis (Vander Heiden et al, 
2001). It has been recently shown that Bcl-xL is associated with cisplatin chemoresistance 
in cancer cells (Villedieu et al., 2007), and drug sensitization occurred with introducing 
Bcl-xL small interfering RNA (Lei et al., 2007). Interestingly, our data suggested possible 
sensitization on melanoma towards apoptosis by simultaneously targeting anti-apoptotic 
Mcl- l and Bcl-xL with FAS inhibitor. 
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Cytochrome c, the respiratory component in mitochondria, is one of the apoptotic 
factors discharged into the cytosol, recruiting apoptosis protease activating factor (Apaf-1) 
and procaspase-9 to form apoptosome. This activates caspase-9, downstream caspase-3 and 
other effector molecules to bring about cell death (Rodriguez and Lazebnik, 1999). We 
found in this study that after the FAS inhibitor treatment, cytochrome c was released (Fig. 
3.15) and caspase-9 was activated (Fig. 3.13)，indicating the execution of the mitochondrial 
apoptotic pathway. Apart from cytochrome c, the FAS inhibitor also induced Smac/Diablo 
release (Fig. 3.15). 
Smac/Diablo is a 21 kDa mammalian mitochondrial protein which is released into the 
cytosol upon mitochondrial stress (Du et al” 2000; Verhagen et al., 2000) and competes 
with caspases for binding of lAPs (inhibitor of apoptosis proteins) to relieve the inhibitory 
effect of the lAPs on caspases (Srinivasula et al., 2001). In mammalian cells, the lAP 
family members include C-IAPl, C-IAP2, XIAP, survivin, livin and NAIP. Recent reports 
have shown that LAP proteins are over-expressed in cancer cell lines and primary tumors 
and play a very crucial role in cancer progression (Altieri et al., 1999; Tamm et al., 2000). 
Our data showed that cerulenin and CIS significantly depleted survivin and XIAP proteins 
(Fig. 3.16). Survivin, the smallest mammalian member of lAP with molecular mass of 16.5 
kDa, is highly expressed in fetal development and malignant cancer cells (Reed & Reed, 
1999). Through caspase-3 inhibition, survivin interacts with microtubules in mitosis, 
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overcomed G2/M-phase checkpoint to favour aberrant progression of transformed cells (Li 
et al., 1998). In vivo studies also showed that apoptosis was inhibited with transgenic 
expression of survivin in melanoma cells (Grossman et al., 2001). Blockade of survivin 
expression by introducing small interfering RNA induced caspase-dependent apoptosis in 
colorectal cancer (Williams et al., 2003). Besides survivin, as mentioned before, XIAP was 
also found to be depleted after the inhibitor treatment. 
XIAP (X-chromosome-linked lAP) is a 57kDa protein that suppresses cell death by 
inhibiting certain downstream caspases, targeting pro-apoptotic proteins for degradation 
and activating prosurvival signaling cascade via TAKl (MAPKKK) (Listen et al” 2003). 
Treatment on cancer malignancy by antisense oligonucleotdies against XIAP has been 
shown effective in vitro and is currently under evaluation in clinical trials (Schimmer et al； 
2006). Specific downregulation of XIAP and Bcl-2 by RNAi sensitized multi-drug resistant 
MCF-7 human breast cancer cells to chemotherapeutic agents (Lima et al., 2004). 
Molecular analysis has revealed that the amino-terminal residues of Smac/Diablo interact 
with the BIR3 region of XIAP to antagonize it from inhibiting caspase activation (Liu et al., 
2000). As found in this study, the FAS inhibitor caused mitochondrial release of 
Smac/Diablo, so that it might compete with lAPs survivin and XIAP from binding to 
caspase substrates and so rendered the caspases active. The caspase activations might also 
be enhanced due to simultaneous depletion of lAPs. 
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Previous studies on cerulenin- and C75-induced apoptosis mostly focused on the 
mitochondria-mediated apoptotic signaling cascade. Recently, Bandyopadhyay et al. (2006) 
investigated the apoptotic pathway by using FAS siRNA and microarray analysis, and 
colleagues showed recently that the death receptor pathway was also important in the 
induced apoptosis in the breast cancer cells, with elevation of mRNA levels of the 
proapoptotic genes BNIP3，tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), and death-associated protein kinase 2 (DAPK2). Our data also showed that both 
cerulenin and CIS elicited the death-receptor apoptotic pathway in A-375 cells, with 
elevated tumor necrosis factor receptor DR5, rather than TRAIL, and activation of 
caspase-8 (Fig 3.11). 
A-375 and other human melanoma cell lines are TRAIL-resistant. Exogenous 
administering TRAIL/Apo2 did not induce PARP cleavage and DNA fragmentation 
(Chawla-sarkar et al, 2002). The mechanisms of how malignant cells and normal cells 
become resistant to TRAIL-induced apoptosis have not yet been completely elucidated and 
several factors are known to alter their responses to TRAIL, including hypoxia, matrix 
metalloproteinases (MMPs) and cytokines present in the tumor microenvironment (Mace et 
al, 2006). DR5 is one of the receptors for TNF-related TRAIL. DR5 mediates death 
receptor apoptotic pathway and has been targeted for cancer therapy in variety of cell types 
(Thorbum, 2004). It was reported that deletion of DR5 developed resistance to 
81 
‘ Chapter 3 
TRAIL-mediated apoptosis and response to DNA-damaging stimuli (Wu et al, 2000). 
Nevertheless, our studies showed that cerulenin and C75 elevated DR5 level (Fig. 3.11)， 
and administering TRAIL molecules enhanced sensitivity to apoptosis induced by 10 and 
20 [ lM of f a s inhibitors in TRAIL-resistant A-375 cells (Fig. 3.12). At least, such findings 
can prove the important role of DR5 in FAS inhibitor-induced apoptotic signaling cascade 
and its role to abolish TRAIL resistance in A-375 cells. 
Bid is the BH3 domain-only protein that acts as a death agonist of the Bcl-2 family 
(Wang et al., 1996). Bid is localized in the cytosol as an inactive precursor (Luo et al., 
1998) and is cleaved from its full length 22 kDa to its active form 15 kDa by caspase-8 in 
the death-receptor-mediated signaling pathway. Truncated Bid is then translocated to 
mitochondria to sensitize mitochondrial permeabilization and cytochrome c release (Gross 
et al., 1999)，relaying an apoptotic signal from the cell surface to mitochondria. Although 
we could not detect the truncated Bid in the immunoblot, we found in this study depletion 
of full length Bid in the cerulenin- and C75-treated melanoma cells (Fig 3.18). On the other 
hand, our caspase inhibitor studies showed that caspase-8 played an initiative role in the 
caspase-dependent apoptosis induced by the FAS inhibitor (Fig. 3.19). Taken together, we 
hypothesized that a crosstalk may exist between the extrinsic death-receptor pathway and 
the intrinsic mitochondrial apoptotic pathway possibly with Bid as the linker. However, the 
precise molecular mechanism for truncated Bid translocation and the subsequent release of 
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cytochrome c remains to be elucidated. 
Finally, we also showed that the apoptotic cascade initiated by the FAS inhibitors was 
at least caused by their inhibition on FAS activity since molecular depletion of FAS with 
siRNA also elicited a similar cascade. 
In conclusion, the inhibitor retarded FAS activity that resulted in elevation of DR5 and 
sensitized the melanoma cells to apoptosis. Caspase-8 activation and Bid truncation then 
relayed the signals from the death receptors to mitochondria. Depletion of Bcl-2 and Mcl-l 
was resulted which triggered the mitochondrial membrane depolarization and release of 
cytochrome c to activate caspase-9. In meanwhile, the release of Smac/Diablo and 
depletion of lAPs relieved the inhibitory effect on executioner caspase-3. Caspase-3, 
together with other executioner caspases, induced PARP cleavage and caused DNA 
fragmentation to bring the cells to demise (Fig 4.1). 
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Fig. 4.1 The proposed molecular mechanisms of apoptosis induced by FAS inhibition on 
melanoma A-375 cells. 
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CHAPTER 5 Future Prospect 
Amongst the currently-used FAS inhibitors cerulenin, C75, triclosan and orlistat, 
cerulenin was chemical iinnstable (Kuhajda, 2000) and exerted effects other than fatty acid 
inhibition (Lawrence et al, 1999). Despite a synthetic mammalian FAS inhibitor, C75 also 
induced weight loss (Loftus et al, 2000) and stimulated carnitine palmitoyltransferase-1 
(CPT-1) activity with increased fatty acid oxidation (Thupari et al., 2004). Effects of 
triclosan and orlistat were not promising. Even though 5 alpha-reductase inhibitor 
dutasteride and COX-2-specific inhibitor celecoxib were found to suppress lipogenesis, the 
studies were preliminary and not tested on normal counterparts (Schmidt et al., 2007) (Lu 
& Archer, 2007). 
Scientists have paid concerted efforts on developing and discovering more specific 
novel FAS inhibitors to treat cancer with promising effects. McFadden et al. (2005) had 
recently synthesized C93, a novel small-molecule FAS inhibitor candidate that did not 
induce weight loss or stimulate fatty acid oxidation. In addition, C93 also exhibited 
significant antitumor activity and apoptosis against SK0V3 xenografts in athymic mice 
without significant cytotoxicity to proliferating cellular compartments such as bone marrow, 
gastrointestinal tract, or skin (Zhou et al.’ 2007). Detailed molecular pathway of 
C93-induced apoptosis needed further investigation. 
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Anticancer research nowadays focused more on chemoprevention with dietary 
phytochemicals (Surh, 2003) than using pharmacological therapeutic agents. 
Epigallocatechin-3 -gallate (EGCG), an antioxidant and chemopreventive polyphenol 
highly abundant in green tea, was identified to be a potent natural FAS inhibitor by 
selectively suppressing lipogenesis and inducing apoptosis in prostate cancer cells 
(Brusselmans et al” 2003). Further signaling studies revealed that EGCG-induced 
apoptosis involved JNK activation, with elevated Bax expression, mitochondrial membrane 
potential changes, and activation of caspase-9 and caspase-3, in breast cancer cells (Zhao et 
al, 2006b) (Vergote et al., 2002). EGCG also took part in ROS generation and suppressed 
intracellular ATP levels in MCF-7 cells, leading to either apoptosis or necrosis (Hsuuw and 
Chan, 2007). In addition to epigallocatechin-3-gallate, five other flavonoids, namely 
luteolin, quercetin, kaempferol, apigenin, and taxifolin, also markedly suppressed cancer 
cell lipogenesis and induced PARP cleavage in both breast and prostate cancers 
(Brusselmans et al., 2005b). Supplement of exogenous FAS end-product palmitate, 
nevertheless, rescued the cells from flavonoid-induced apoptosis. This provided insights 
that more specific and less harmful FAS inhibitors might be identified in natural food 
products in the near future. 
Recent studies have focused on the synergistic effects between molecular targets in 
carcinogenesis and some currently used anticancer drugs, so as to enhance efficacies of the 
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drugs on cancer patients with lesser side effects. Some cancer cells have got defects in 
apoptotic signaling, rendering the cells resistant to drug-induced cell death. Several reports 
have shown that blockage of FAS expression sensitized these chemoresistant cancer cells 
towards some anticancer drugs, and new pathways of FAS inhibition relating p53 and 
estrogen receptor have been proposed (Menendez et al, 2004 a-h) (Menendez et al., 2005 
a-f). However, researches targeting FAS for cancer therapy have mainly focused on breast 
and prostate cancers, and there is no such similar report on melanoma cells, though with 
moderately high FAS level. We are the first group to identify the molecular mechanisms of 
how FAS inhibition induces apoptosis using A-375 as a model melanoma cell line. Further 
elucidations on the molecular mechanisms of action in apoptosis and cell cycle imposed by 
FAS inhibition can facilitate further research on the synergism between the currently used 
anticancer drug and potential FAS inhibitors from natural products for effective treatment 
of melanoma patients in the near future. 
** Parts of the thesis have been published in the poster presentation in Organization for 
Oncology and Transitional Research S'd Annual Conference on 22 and September 
2006 in Hong Kong. 
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